Status:
COMPLETED
Trial to Assess the Efficacy and Safety of SPM 927 (200, 400, and 600mg/Day) in Subjects With Painful Distal Diabetic Neuropathy
Lead Sponsor:
UCB Pharma
Conditions:
Diabetic Neuropathies
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This phase 3 trial is being conducted at approximately 80 sites in the United States (U.S.) to investigate whether lacosamide (SPM 927) at different doses reduces pain in subjects with diabetic neurop...
Eligibility Criteria
Inclusion
- Diabetic neuropathy
Exclusion
- Subject has previously participated in this trial or subject has previously been assigned to treatment in a trial of the drug under investigation in this trial.
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2005
Estimated Enrollment :
654 Patients enrolled
Trial Details
Trial ID
NCT00135109
Start Date
October 1 2004
End Date
December 1 2005
Last Update
September 22 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Schwarz
RTP, North Carolina, United States, 27709